SEMNUR PHARMACEUTICALS, INC.
SEMNUR PHARMACEUTICALS, INC. (SMNR): 1 pipeline candidate · ~1 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
0.5 months
D/E -1.08 · 0% dilution
Lead: Phase 3
1 candidate
N/A
N/A
A transparent, data-derived signal for SEMNUR PHARMACEUTICALS, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$230.2M
Cash
$103K
Quarterly Burn
$2.7M
Runway
0.5 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (1 candidate)
| Drug | Phase |
|---|---|
| sp-102 | Phase 3 |
Frequently asked questions
How many drug candidates are in SEMNUR PHARMACEUTICALS, INC.'s pipeline?
SEMNUR PHARMACEUTICALS, INC. (SMNR) has 1 pipeline candidate tracked by BioSniper across SEC filings and clinical trial registrations.
What is SEMNUR PHARMACEUTICALS, INC.'s lead drug candidate?
SEMNUR PHARMACEUTICALS, INC.'s most advanced tracked candidate is sp-102 (Phase 3) for Lumbosacral Radicular Pain.
What is SEMNUR PHARMACEUTICALS, INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, SEMNUR PHARMACEUTICALS, INC. has approximately 0.5 months of cash runway.
What is SEMNUR PHARMACEUTICALS, INC.'s market capitalization?
SEMNUR PHARMACEUTICALS, INC.'s market capitalization is approximately $230.2M.
Who is the CEO of SEMNUR PHARMACEUTICALS, INC.?
Dr. Henry H. Ji Ph.D. is the chief executive officer of SEMNUR PHARMACEUTICALS, INC. (SMNR).
Get the full picture on SEMNUR PHARMACEUTICALS, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.